8,901 Shares in Inhibrx Biosciences, Inc. $INBX Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,901 shares of the company’s stock, valued at approximately $703,000.

A number of other hedge funds have also recently bought and sold shares of INBX. Caligan Partners LP acquired a new position in Inhibrx Biosciences during the third quarter worth about $7,961,000. Readystate Asset Management LP grew its holdings in Inhibrx Biosciences by 534.1% during the third quarter. Readystate Asset Management LP now owns 170,158 shares of the company’s stock worth $5,731,000 after acquiring an additional 143,324 shares during the period. UBS Group AG grew its holdings in Inhibrx Biosciences by 681.9% during the fourth quarter. UBS Group AG now owns 73,699 shares of the company’s stock worth $5,822,000 after acquiring an additional 64,273 shares during the period. Citadel Advisors LLC acquired a new position in Inhibrx Biosciences during the third quarter worth about $1,926,000. Finally, SummitTX Capital L.P. acquired a new position in Inhibrx Biosciences during the third quarter worth about $1,824,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Zacks Research raised Inhibrx Biosciences to a “hold” rating in a report on Thursday, April 9th. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Stifel Nicolaus initiated coverage on Inhibrx Biosciences in a research report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $150.00.

Inhibrx Biosciences Trading Down 0.0%

NASDAQ:INBX opened at $103.95 on Friday. The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. Inhibrx Biosciences, Inc. has a 1-year low of $12.72 and a 1-year high of $155.29. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -12.39 and a beta of 3.88. The stock has a fifty day simple moving average of $94.72 and a 200 day simple moving average of $84.06.

Inhibrx Biosciences (NASDAQ:INBX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). Sell-side analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 earnings per share for the current year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.